Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).
Daisaku YamadaShogo KobayashiHidenori TakahashiYoshifumi IwagamiHirofumi AkitaKei AsukaiJunzo ShimizuTerumasa YamadaMasahiro TanemuraShigekazu YokoyamaMasanori TsujieTadafumi AsaokaYutaka TakedaOsakuni MorimotoAkira TomokuniYuichiro DokiHidetoshi EguchiPublished in: Annals of surgical oncology (2024)
This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.